# Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)

Source: https://welltoldgrants.com/grants/rfa-da-25-049-solutions-to-enable-diagnosis-and-treatment-of-adverse/  
Official notice: https://www.grants.gov/search-results-detail/354932

> National Institutes of Health offered grants to small businesses. Applications closed on December 2, 2024.

| Field | Value |
|---|---|
| Opportunity number | RFA-DA-25-049 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | December 2, 2024 |
| Award ceiling | not stated |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.279 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

## What the grant funds

This funding opportunity calls for developing novel solutions targeted to improve health outcomes and reduce the impact of adverse health consequences in people who use drugs. These solutions should maximize accessibility and affordability, ideally designed to be implemented in mobile community-based care systems and able to reach the vulnerable and underserved population with limited engagement with conventional healthcare services. Solutions could be based on original technologies or existing technologies already available that could be repurposed to target the specific needs of people who use drugs.

## Questions people ask

### Is RFA-DA-25-049 still open?

No. It closed on December 2, 2024.

### Who can apply for Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)?

Closed December 2, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### Who has been funded under RFA-DA-25-049?

NIH RePORTER lists 3 projects funded under RFA-DA-25-049 in fiscal 2026, at 3 institutions. The most were at Virogenomics Biodevelopment, Inc., Transchromix, LLC., Edi Therapeutics LLC.

### Who has won Drug Use and Addiction Research Programs grants before?

The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.